Syneos Health and Aetion Partner to Offer RWE Solutions
Syneos Health and Aetion announced a partnership to provide regulatory-grade data and analytics-driven solutions to advance drug development and improve patient outcomes.
The partnership brings together Syneos Health’s proprietary data collection and research solutions with Aetion Evidence Platform (AEP) to generate evidence through patient data curation and real-world data.
Syneos Health’s offerings, including its Biopharmaceutical Acceleration Model, Dynamic Assembly, and RWE Solutions, enable biopharmaceutical companies to accelerate product development and patient access to new therapies; reduce risk through evidence-based decision-making; and demonstrate value to a broad healthcare ecosystem, including patients, regulators, payers, and health care providers. Aetion’s AEP analyzes data from the real world—including claims, electronic health records, registries, and clinical trial data—to produce transparent, rapid, and scientifically validated real-world evidence on the safety, effectiveness, and value of medical interventions.
Read more about the partnership here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
